Chronic Venous Occlusions Treatment Market - By Product, By Application, By End Use - Global Forecast, 2025-2034

Chronic Venous Occlusions Treatment Market Size

The global chronic venous occlusions treatment market was valued at USD 7 billion in 2024. The market is expected to reach from USD 7.4 billion in 2025 to USD 11.2 billion in 2034, growing at a CAGR of 4.7% during the forecast period, according to the latest report published by Global Market Insights Inc. Increasing incidence of venous disorders, increasing aging population, technological innovations, and raising awareness propel growth in the market.

The market for treatment of chronic venous occlusions offers innovative healthcare solutions to providers, payers, healthcare technology companies, and life sciences organizations to improve patient outcomes, regulatory compliance, and operational effectiveness. The solutions cover minimally invasive devices, pharmaceuticals, compression therapy, and digital solutions that enable effective diagnosis, treatment, and long-term disease management.
 

Some of the major players in the market are 3M, Bayer AG, Becton Dickinson (BD), Boston Scientific Corporation, and Viatris. These firms preserve their competitive edge by ongoing innovation in products, strong international presence, strategic alliances, and enormous research and development investments to support increasing clinical demands and increase their market footprint.
 

The market has increased from USD 5.8 billion in 2021 and reached USD 6.6 billion in 2023. One of the most significant drivers is the rising prevalence of venous diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and chronic venous insufficiency, conditions that are increasing due to sedentary lifestyles, obesity, and the aging global population. With the elderly population being more vulnerable to venous disorders, the demand for effective and long-term treatment solutions is steadily rising. In addition, rapid technological advancements, including minimally invasive surgical instrument, innovative stent technologies, compression therapy systems, and advanced imaging solutions, are improving diagnosis, procedural outcomes, and recovery times, thereby fueling adoption rates.
 

The growing awareness among patients and healthcare providers regarding early diagnosis and treatment options is also playing a crucial role in market expansion, supported by educational campaigns and patient advocacy programs. Furthermore, the market benefits from rising healthcare expenditures and medical device reimbursement support for venous interventions, particularly in developed regions. Pharmaceutical advancements, including anticoagulants and thrombolytic agents from leading companies such as Bayer, Pfizer, and Sanofi, further strengthen therapeutic offerings, providing patients with effective medication-based solutions.
 

Strategic collaborations among medical device companies, pharmaceutical firms, and healthcare providers are accelerating innovation and broadening market access globally. Additionally, the increasing penetration of digital health technologies and telemedicine is enhancing post-treatment monitoring and patient engagement.
 

Chronic venous occlusions treatment refers to medical approaches, including minimally invasive procedures, pharmaceuticals, compression therapies, and digital health tools, aimed at restoring blood flow, alleviating symptoms, preventing complications, and improving quality of life for patients with long-standing venous blockages caused by thrombosis, scarring, or vascular abnormalities.
 

Chronic Venous Occlusions Treatment Market Trends

The growing incidence of varicose veins, along with increasing awareness for its treatment, is a key driver of the market. Varicose veins and associated chronic venous insufficiency diseases are on the rise due to sedentary lifestyles, obesity, aging populations, and hereditary factors, resulting in an increased number of patients presenting for diagnosis and management.
 

• On a microeconomic front, the trend fuels demand for new, minimally invasive treatments like stenting, laser-based therapies, and compression devices, leading hospitals and healthcare providers to invest in high-end treatment solutions. Patients are in growing demand for early detection and efficient therapeutic treatment, which leads to a competitive market for medical device manufacturers, pharmaceutical firms, and service providers.
   
• Players that can offer efficient, safe, and cost-effective treatment solutions are positioned to gain market share, while smaller providers may experience pressure to differentiate their offerings through technological innovation and superior patient outcomes.
   
• From a macroeconomic perspective, rising healthcare expenditures, improving reimbursement policies, and government initiatives promoting preventive care further support market expansion. Countries with aging populations, particularly in Europe, North America, and parts of Asia-Pacific, are experiencing higher prevalence of chronic venous diseases, which stimulates investment in healthcare infrastructure and advanced treatment modalities.
   
• Additionally, increasing public awareness campaigns, patient advocacy programs, and educational initiatives have enhanced knowledge about venous disease symptoms and available therapies, encouraging timely interventions and reducing long-term complications. The combination of growing disease prevalence, heightened patient awareness, and supportive economic and policy frameworks is creating a favorable environment for sustained growth in the market, as providers and payers seek to optimize clinical outcomes while addressing the rising burden of venous disorders globally.
   

Chronic Venous Occlusions Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the product, the chronic venous occlusions treatment market is bifurcated into devices, and drugs. The devices segment is further divided into compression devices, sclerotherapy, endovenous ablation, vein stripper, and other devices. The devices segment has asserted its dominance in the market by securing a significant market share of 52.9% in 2024, owing to the increasing preference for minimally invasive therapies and increased adoption of compression and endovenous treatment devices boost market demand. The segment is expected to exceed USD 5.6 billion by 2034, growing at a CAGR of 4.2% during the forecast period.
 

On the other hand, the drugs segment is further divided into analgesics, antibiotics, anticoagulants, and other drugs. The segment is expected to grow with a CAGR of 5.3%. The growth of this segment can be attributed to the increasing use of anticoagulants and pharmacologic therapies for venous disorders drives expansion of the drugs segment in the market.
 

• The devices segment is fueled by the expanding preference for minimally invasive treatments and growing use of advanced compression and endovenous treatment devices. Patients and physicians increasingly are turning to such procedures as sclerotherapy, endovenous ablation, and compression device use because they have less procedural risk, fewer days of recovery, and better clinical results than older methods like vein stripping.
   
• Technological advancements in device design, including more precise ablation catheters, adjustable compression systems, and user-friendly applicators, have further enhanced patient compliance and treatment efficacy. Additionally, the growing awareness about venous disorders among patients and physicians has resulted in higher demand for early diagnosis and intervention, boosting device utilization.
   
• Rising investments in research and development by leading medtech companies and the expansion of outpatient and ambulatory care centers provide additional support for segment growth. Favorable reimbursement policies in developed regions, coupled with an aging population prone to venous disorders, further accelerate adoption of medical devices, positioning this segment for steady long-term growth.
   
• The drugs segment held a revenue of USD 3.3 billion in 2024, with projections indicating a steady expansion at 5.3% CAGR from 2025 to 2034. The drugs segment is witnessing significant growth due to the increasing use of anticoagulants and pharmacologic therapies in managing chronic venous occlusions and related venous disorders. Anticoagulants, thrombolytic agents, and analgesics are widely prescribed to prevent blood clot formation, reduce inflammation, and alleviate pain associated with venous insufficiency and deep vein thrombosis.
   
• The rising prevalence of chronic venous diseases, particularly among aging populations and individuals with sedentary lifestyles or comorbidities, is driving consistent demand for pharmaceutical management. Moreover, advancements in drug formulations, including extended-release and targeted delivery mechanisms, have improved patient compliance and therapeutic outcomes.
   
• Growing awareness among physicians and patients regarding the benefits of early pharmacologic intervention further fuels market expansion. Increasing global healthcare expenditure, coupled with favorable regulatory approvals for novel anticoagulants and supportive reimbursement frameworks, enables broader accessibility.
   

Based on application, the chronic venous occlusions treatment market is classified into varicose veins, edema, deep vein thrombosis, venous stasis ulcers, and other applications. The varicose veins segment dominated the market with a revenue share of 48.7% in 2024 and is expected to reach USD 5.4 billion within the forecast period.
 

• The segment of varicose veins leads the market because of the increasing incidence of venous insufficiency and allied complications. Sedentary life, obesity, prolonged standing, and age are major contributing factors to the development of varicose veins, especially in adults aged 40+, resulting in an expanding pool of patients opting for treatment. Enhanced awareness of patients and practitioners alike regarding less invasive procedures like endovenous laser ablation, radiofrequency ablation, and sclerotherapy has further pushed market uptake.
   
• Advances in device technology, increased procedural safety, and shorter recovery times have also boosted physician preference and patient acceptance of these procedures. Further, increasing disposable incomes and increased reimbursement coverage in developed countries favor greater access to varicose vein treatments.
   
• The edema segment held a revenue of USD 1.9 billion in 2024, with projections indicating a steady expansion at 5.2% CAGR from 2025 to 2034. The edema segment is growing rapidly in the market due to the increasing prevalence of chronic venous insufficiency, lymphedema, and post-surgical fluid retention conditions. Patients with venous disorders, cardiovascular diseases, or obesity frequently develop lower limb swelling, prompting demand for effective management solutions.
   
• Advanced compression therapies, including multi-layer bandages, pneumatic devices, and wearable compression systems, play a crucial role in alleviating edema symptoms, improving mobility, and preventing disease progression. Furthermore, rising patient education campaigns and digital health monitoring tools help in early intervention and long-term management.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the chronic venous occlusions treatment market is classified into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 65.1% in 2024 and is expected to reach USD 7.2 billion within the forecast period.
 

• The two largest segments account for over 87.4% of the total market value. The hospitals segment leads the market as it has extensive infrastructure, has specialized healthcare professionals available, and there is access to cutting-edge diagnostic and therapeutic technologies. Hospitals offer comprehensive care, having procedures like minimally invasive stent placements, catheter-directed thrombolysis, and complex pharmacological management for chronic venous occlusions, which involve advanced equipment and skilled interventionists.
   
• Increasing incidence of venous disorders in the elderly and comorbid populations like diabetes or cardiovascular diseases fuels increased patient traffic towards hospitals, increasingly driving the revenue share. Hospitals also have the advantage of strong reimbursement patterns and insurance coverage, which motivates patients to seek treatments in hospitals.
   
• The ambulatory surgical centers segment held a revenue of USD 1.6 billion in 2024, with projections indicating a steady expansion at 5.1% CAGR from 2025 to 2034. ASCs are emerging as a significant growth segment in the market, driven by the rising preference for outpatient procedures and minimally invasive therapies. ASCs offer cost-effective, convenient care for patients requiring venous interventions, such as endovenous laser ablation, sclerotherapy, and catheter-directed procedures, without the need for extended hospital stays.
   
• Patients increasingly prefer ASCs due to reduced procedural costs, shorter waiting times, and personalized care, which enhances patient satisfaction and adherence to treatment plans. The combination of patient-centric care, economic efficiency, and technological adoption positions ASCs as a dynamic and rapidly expanding segment within the market.
   

Looking for region specific data?

Download Free PDF

North America Chronic Venous Occlusions Treatment Market
 

The North America market dominated the global market with a market share of 40.1% in 2024.
 

• The North America market for treating chronic venous occlusions dominates worldwide, thanks to a mix of superior healthcare infrastructure, high prevalence of diseases, and robust acceptance of new therapies. The region has the advantage of a fast-evolving aging population, which has greater susceptibility towards venous diseases like varicose veins, deep vein thrombosis, and chronic venous insufficiency, thus having direct demand for sophisticated interventions.
   
• Strong awareness drives by healthcare professionals, advocacy organizations, and government drives early diagnosis and treatment, thus increasing patient bases further. Technologically, North America is the hotbed of innovation with major players Boston Scientific, Medtronic, and 3M launching minimally invasive devices, stents, and compression systems backed by large clinical trials.
   
• Favorable reimbursement policies, high healthcare spending, and wide insurance coverage ensure accessibility to both procedural and pharmaceutical treatments, stimulating overall adoption. Moreover, increasing outpatient procedure volumes in ambulatory surgical centers and ongoing investments in telehealth and digital monitoring tools are enhancing care delivery efficiency, solidifying North America’s dominance in the market.
   

The U.S. chronic venous occlusions treatment was valued at USD 2.2 billion and USD 2.3 billion in 2021 and 2022, respectively. The market size reached USD 2.6 billion in 2024, growing from USD 2.4 billion in 2023.
 

• The U.S. chronic venous occlusions treatment market is driven by high disease prevalence, advanced care infrastructure, and a strong ecosystem of leading medical device and pharmaceutical companies. Lifestyle factors such as obesity, sedentary work habits, and a growing elderly population contribute significantly to the rising incidence of varicose veins, deep vein thrombosis, and chronic venous insufficiency.
   
• This creates consistent demand for advanced treatments, including minimally invasive procedures, endovenous devices, and pharmacological solutions. The U.S. also benefits from strong patient awareness, with widespread educational initiatives and screening programs that encourage early diagnosis and prompt treatment. From an economic perspective, robust healthcare spending and favorable reimbursement structures make both hospital-based and outpatient treatments accessible to large patient groups.
   
• Additionally, the presence of major market leaders such as Boston Scientific, Medtronic, and Pfizer ensures continuous innovation and rapid adoption of next-generation products. Growth in outpatient settings, particularly ambulatory surgical centers, and the increasing role of digital health technologies for follow-up and patient monitoring further support market expansion in the U.S.
   

Europe Chronic Venous Occlusions Treatment Market
 

Europe market accounted for USD 2 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Among the main drivers is the rapidly aging population in this region, which has a higher incidence of venous diseases like varicose veins, deep vein thrombosis (DVT), and chronic venous insufficiency. Growing rates of obesity and inactive lifestyles also contribute to the disease burden, creating high demand for effective treatments.
   
• The area enjoys well-developed healthcare infrastructure, ample healthcare expenditure, and positive reimbursement systems that enable access to sophisticated treatment technologies, such as minimally invasive technologies, stents, compression systems, and pharmaceutical therapies. European patient awareness levels are much higher than those of many other areas, underpinned by good advocacy programs and public health programs
   
• Additionally, technological advancements and the presence of leading global medtech and pharmaceutical companies in Europe facilitate continuous innovation and product adoption.
   

Germany dominates the European chronic venous occlusions treatment market, showcasing strong growth potential.
 

• The country has a high prevalence of venous disorders, particularly among its aging population, with chronic venous insufficiency and varicose veins being widespread conditions. This drives demand for both surgical and minimally invasive treatment solutions. German hospitals and specialty clinics are early adopters of innovative technologies such as endovenous laser ablation, radiofrequency ablation, and advanced stent placements, further fueling market expansion.
   
• On a macroeconomic level, Germany’s high healthcare expenditure, comprehensive insurance coverage, and government initiatives supporting preventive care create favorable conditions for growth. Additionally, strong collaborations between academic institutions, research centers, and global medtech companies enable faster clinical adoption of cutting-edge therapies.
   
• From a microeconomic perspective, growing patient awareness, increasing outpatient treatments, and the emphasis on cost-effective yet efficient care delivery contribute to Germany’s leadership role within the European market.
   

Asia Pacific Chronic Venous Occlusions Treatment Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 5.7% during the analysis timeframe.
 

• An ageing population at a fast pace, especially among nations like Japan, South Korea, and Australia, is raising the number of chronic venous insufficiency, varicose veins, and deep vein thrombosis. Increased incidences of obesity, physical inactivity, and the rising burden of cardiovascular comorbidities are also contributing to disease incidence.
   
• At the macroeconomic level, growing healthcare spending, government emphasis on healthcare infrastructure, and reimbursement reforms in developed and emerging markets are driving adoption of advanced treatments.
   
• Microeconomic drivers involve growing multinational medical device company presence, local production of cost-saving compression therapies, and mounting awareness campaigns urging patients to come in earlier for treatment. Further, the latest technologies in minimally invasive stent placements and endovenous procedures are being increasingly adopted by providers.
   

China chronic venous occlusions treatment market is estimated to grow with a significant CAGR, in the Asia Pacific chronic market.
 

• The country’s rapidly aging population, coupled with high smoking rates, growing obesity, and a surge in cardiovascular and metabolic disorders, is significantly contributing to the rising incidence of chronic venous diseases. Macroeconomic factors such as strong government investment in healthcare infrastructure, expansion of universal health insurance coverage, and policy emphasis on non-communicable disease management are fostering greater access to treatment.
   
• On the microeconomic side, the presence of global players like Medtronic, Boston Scientific, and Bayer, alongside a rapidly growing domestic medtech sector, is enhancing treatment availability and driving innovation in cost-effective solutions.
   
• Furthermore, increased public awareness campaigns, urban lifestyle changes, and greater patient willingness to adopt minimally invasive therapies are supporting demand. With continuous improvements in hospital infrastructure, skilled physician training, and wider availability of advanced devices, China is expected to remain a key growth driver in the Asia Pacific market.
   

Latin American Chronic Venous Occlusions Treatment Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Chronic venous insufficiency and varicose veins are common in Brazil due to genetic factors, lifestyle patterns, and an aging population, creating a large patient pool in need of advanced treatment. The growing adoption of minimally invasive therapies such as endovenous laser ablation, radiofrequency ablation, and stent placements reflects increasing demand for safer, quicker recovery options.
   
• On a microeconomic level, private healthcare providers and specialized vascular clinics are expanding their offerings, investing in advanced devices and pharmaceuticals to meet patient expectations. Public awareness campaigns and growing preference for aesthetic and functional treatments also stimulate market growth.
   
• Macroeconomic factors such as rising healthcare expenditures, supportive government programs to strengthen access to tertiary care, and favorable reimbursement for venous procedures further accelerate adoption. Additionally, the presence of international medical device companies and local partnerships ensures accessibility to innovative therapies, strengthening Brazil’s leading role in the region.
   

Middle East and Africa Chronic Venous Occlusions Treatment Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia represents one of the fastest-growing markets for chronic venous occlusions treatment in the Middle East, driven by increasing lifestyle-related risk factors, urbanization, and the country’s rapidly expanding healthcare infrastructure. Venous disorders, including varicose veins and deep vein thrombosis, are becoming more prevalent due to sedentary lifestyles, rising obesity rates, and an aging demographic, creating strong demand for effective treatment solutions.
   
• On a microeconomic level, private hospitals and specialty clinics are adopting advanced minimally invasive procedures, supported by growing investments from both local and international healthcare players. Patient awareness of venous diseases and their long-term complications is rising, leading to early diagnosis and higher treatment uptake.
   
• Macroeconomic factors such as Saudi Arabia’s Vision 2030 initiative, which prioritizes healthcare modernization, coupled with rising per capita healthcare spending, strongly support the integration of cutting-edge technologies.
   

Chronic Venous Occlusions Treatment Market Share

The market is highly competitive, with leading medical device and pharmaceutical companies focusing on product innovation, advanced technologies, and strategic collaborations to strengthen their market positions. With the rising burden of venous diseases and increasing demand for minimally invasive solutions, companies are leveraging research and development investments, digital health integration, and AI-driven diagnostic tools to enhance treatment precision and improve patient outcomes. The global shift toward value-based healthcare is also compelling players to emphasize cost-effective, outcome-oriented therapies and expand their presence in emerging markets.
 

Key players include Boston Scientific Corporation, Medtronic, Gore, 3M, and Cook Medical, collectively accounting for a 40.5% share of the global market. These companies maintain leadership through robust product portfolios, strong global distribution networks, and continuous advancements in stent technologies, compression therapy systems, and interventional devices. Their dominance is reinforced by strategic partnerships with hospitals, ambulatory centers, and healthcare providers to improve accessibility and expand treatment adoption.
 

At the same time, smaller and niche players are gaining momentum by focusing on specialized therapies, patient-centric devices, and region-specific solutions. Competitive differentiation is increasingly defined by the ability to deliver minimally invasive, technologically advanced, and cost-efficient treatment modalities tailored to diverse healthcare systems worldwide. As the market evolves, competition is expected to intensify, with both global leaders and emerging firms pursuing mergers, acquisitions, and digital innovation to capture greater market share and meet the growing clinical demand for effective chronic venous occlusions treatments.
 

Chronic Venous Occlusions Treatment Market Companies

Few of the prominent players operating in the chronic venous occlusions treatment industry include:

• 3M
• AngioDynamics
• Bayer AG
• Boston Scientific Corporation
• Coloplast
• ConvaTec
• Cook Medical
• Gore
• Leucadia Pharmaceuticals (Hikma)
• Medtronic
• Pfizer
• Sanofi
• Sciton
• Tactile Medical
• Terumo
• Viatris
   
•  Boston Scientific Corporation

Boston Scientific Corporation leads the chronic venous occlusions treatment market with a share of 12% in 2024. Boston Scientific’s USP in lies its advanced minimally invasive vascular solutions, including venous stents and interventional devices. The company leverages continuous research and development, strong clinical trial support, and global distribution to deliver effective, safe, and durable treatment outcomes for complex venous conditions.
 

•  Medtronic

Medtronic’s USP is its comprehensive vascular care portfolio, combining cutting-edge catheter-based therapies, imaging solutions, and minimally invasive technologies. The company emphasizes innovation, global presence, and integration of digital health tools, enabling providers to optimize treatment outcomes and patient recovery while addressing the growing burden of chronic venous occlusions worldwide.
 

Chronic Venous Occlusions Treatment Industry News:

• In April 2024, Johnson & Johnson unveiled new results from the PIONEER AF-PCI clinical trial at the American College of Cardiology’s 73rd Annual Scientific Session & Expo in Atlanta, Georgia. Findings demonstrated that XARELTO (rivaroxaban) outperformed warfarin in reducing clinically significant bleeding (CSB) and net adverse clinical events (NACE) in patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), underscoring its benefits for both elderly and non-elderly patients.
   
• In April 2024, AngioDynamics Inc. received FDA clearance for its AlphaVac F1885 System, expanding its use to treat pulmonary embolism (PE). This milestone broadens the system’s clinical applications, enabling the non-surgical removal of thrombi or emboli from the venous vasculature and marking a significant advancement in critical interventional care.
   
• In May 2022, THERACLION, a pioneering company in scalable robotic platforms for non-invasive echotherapy, launched SONOVEIN HD. This innovative system combines the advanced imaging technology of SuperSonic Imagine-recently acquired by Hologic-with the world’s first and only extracorporeal therapeutic ultrasound solution, establishing a new benchmark in non-invasive venous treatments.
   
• In April 2022, I-VASC, an Italian medical device innovator, secured EUR 1.8 million in Series A funding to commercialize its VELEX device. Specifically designed for Empty Vein Ablation, VELEX addresses chronic venous insufficiency (CVI) and varicose veins. The device, which received CE Mark approval in May 2021, represents a significant milestone in advancing minimally invasive venous disorder therapies.
   

The chronic venous occlusions treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Billion from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Devices
  • Compression devices
  • Sclerotherapy
  • Endovenous ablation
    • Laser ablation
    • Radiofrequency ablation
  • Vein stripper
  • Other devices 
• Drugs
  • Analgesics
  • Antibiotics
  • Anticoagulants
  • Other drugs

Market, By Application

• Varicose veins
• Edema
• Deep vein thrombosis
• Venous stasis ulcers
• Other applications

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE